


An Application Data Sheet was filed in reference to this application on September 26, 2005.

Page 1 of 2 Pages

☒ Original ☐ Substitute ☐ Supplemental

Atty. Docket: NYKJAER2

COMBINED DECLARATION (37 CFR 1.63) AND POWER OF ATTORNEY FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

TITLE OF THE INVENTION	USE OF COMPOUNDS FOR THE PREVENTION OF DRUG-INDUCED CELL TOXICITY
<p>This declaration is directed to:</p> <p><input type="checkbox"/> the attached application;</p> <p><input type="checkbox"/> the application filed in the United States under 35 U.S.C. §111 on _____, as U.S. Appln. No. _____*; or</p> <p><input checked="" type="checkbox"/> the application which was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international (PCT) application, <u>PCT/DK2004/000205</u>; filed March 25, 2004, entry requested on *; national stage application received U.S. Appln. No. 10/550,488; §371/§102(e) date _____* (* if known)</p> <p><input type="checkbox"/> as amended on _____ (if applicable).</p> <p>I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;</p> <p>I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;</p> <p>I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.</p> <p>All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.</p> <p>As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:</p> <p align="center">All of the practitioners associated with Customer Number 001444</p> <p>Direct all correspondence to the address associated with Customer Number 001444, which is presently:</p> <p align="center">BROWDY AND NEIMARK, P.L.L.C. 624 Ninth Street, N.W. Washington, D.C. 20001-5303 (202) 628-5197</p> <p>The undersigned hereby authorizes the U.S. Attorneys or Agents appointed herein to accept and follow instructions from <u>HOIBERG A/S</u> as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. Attorneys or Agents and the undersigned. In the event of a change of the persons from whom instructions may be taken, the U.S. Attorneys or Agents appointed herein will be so notified by the undersigned.</p>	
<p>FULL NAME OF INVENTOR(S)</p> <p>Inventor one: <u>Anders NYKJAER</u> Date: <u>NOVEMBER 22, 2005</u></p> <p>Signature: <u></u> Citizen of: <u>Denmark</u></p> <p>Inventor two: _____ Date: _____</p>	

Title: USE OF COMPOUNDS FOR THE PREVENTION OF DRUG-INDUCED CELL TOXICITYU.S. Application filed _____, Serial No. 10/550,488PCT Application filed March 25, 2004, Serial No. PCT/DK2004/000205

Signature: _____ Citizen of: _____

Inventor three: _____ Date: _____

Signature: _____ Citizen of: _____

Inventor four: _____ Date: _____

Signature: _____ Citizen of: _____

Inventor five: _____ Date: _____

Signature: _____ Citizen of: _____

☐ Additional inventors or a legal representative are being named on _____ additional form(s) attached hereto.

All inventors must review application and declaration before signing. All alterations must be initialed and dated by all inventors prior to execution. No alterations can be made after the declaration is signed. All pages of the declaration must be seen by all inventors.

Resolving conflicts between Application Data Sheets and Declaration occurs as follows: (1) normally, the latest submitted information governs, (2) if an Application Data Sheet and a declaration are filed the same day, the Application Data Sheet governs, except with respect to the naming of inventors and the identification of their citizenship. See 37 CFR 1.76(d).